---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024727"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:35:33.125932+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prelude Q3 net loss $30.0M; FDA clears two INDs, halts PRMT5 internal development

## Summary
- Net loss of $30.0M ($0.63 per share) vs $30.7M ($0.66) in Q3 2021.
- Cash, equivalents & marketable securities $224.0M; runway into Q4 2024.
- FDA cleared INDs for PRT3789 (SMARCA2 degrader) and PRT3645 (brain-penetrant CDK4/6 inhibitor).
- Discontinues internal PRMT5 program (PRT543, PRT811) to focus on higher-potential assets.
- PRT2527 CDK9 Phase 1 dose escalation on track for RP2D by year-end; no dose reduction AEs.

## SEC filing metadata
- accession: 0000950170-22-024727
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017022024727/0000950170-22-024727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017022024727/prld-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024727
- JSON: https://secwatch.observer/filing/0000950170-22-024727.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024727.txt

## Key facts
- Earnings Releases
  Prelude Therapeutics Inc reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017022024727/0000950170-22-024727-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.